Topical Treatment for Pediatric Rashes Due to Hypersensitivity Reactions

First-Line Treatment Options

• Mild to moderate potency topical corticosteroids are recommended as first-line therapy for hypersensitivity-related rashes in pediatric patients, according to the American Academy of Dermatology 1
• Younger patients (0-6 years), especially infants, are more vulnerable to hypothalamic-pituitary-adrenal (HPA) axis suppression due to their high body surface area-to-volume ratio compared to older children, as noted by the Journal of the American Academy of Dermatology 2, 1
• High-potency or ultra-high-potency topical corticosteroids should be avoided or used with extreme caution in infants and young children, as recommended by the American Academy of Dermatology 1

Application Guidelines

• Apply a thin film of the corticosteroid to the affected area once or twice daily, as suggested by the American Academy of Dermatology 1
• Treatment should not be applied more than twice daily, according to the BMJ 3
• Duration of treatment should be limited to the shortest period necessary to achieve control of symptoms, as recommended by the American Academy of Dermatology 1
• For acute flares, a short course (3-7 days) is typically sufficient, according to the American Academy of Dermatology 1

Alternative Options for Sensitive Areas

• Tacrolimus 0.03% ointment and pimecrolimus 1% cream are effective alternatives for sensitive areas such as the face and genital regions, as noted by the Journal of Microbiology, Immunology and Infection and the American Academy of Dermatology 4, 1
• Tacrolimus 0.1% ointment has shown excellent improvement within 30 days in pediatric patients with facial rashes, according to the Journal of the American Academy of Dermatology 2

Adjunctive Treatments

• Regular use of emollients has a short and long-term steroid-sparing effect, as noted by the Journal of Microbiology, Immunology and Infection 4
• Sedating antihistamines may be useful as short-term adjuncts during severe itching episodes, according to the BMJ and the American Academy of Dermatology 3, 1

Special Considerations

• For severe or recalcitrant cases, wet wrap therapy can be considered, as suggested by the Journal of Microbiology, Immunology and Infection 4
• Secondary bacterial infections (usually Staphylococcus aureus) require antibiotic treatment, according to the BMJ and the American Academy of Dermatology 3, 1

Safety Considerations and Monitoring

• Provide careful instruction to caregivers on the amount to apply and safe sites for use, as recommended by the Journal of the American Academy of Dermatology 2
• Monitor for signs of skin atrophy, striae, or systemic absorption, according to the Journal of the American Academy of Dermatology 2
• The risk of adverse effects increases with higher potency, occlusion, and prolonged use, as noted by the American Academy of Dermatology 1

Topical Treatments for Pediatric Hypersensitivity Rashes

Alternative Topical Treatments

• Ichthammol (1% in zinc ointment) is less irritant than coal tars and can be applied as an ointment or in paste bandages, particularly useful for lichenified areas 5, 6
• Coal tar solution (1% in hydrocortisone ointment) can be effective and does not cause systemic side effects unless used excessively 5

Management of Complications

• For secondary bacterial infections (usually Staphylococcus aureus), appropriate antibiotic treatment should be initiated, with flucloxacillin typically being the most appropriate antibiotic for S. aureus infections; erythromycin may be used for penicillin-allergic patients 6
• For herpes simplex infections (eczema herpeticum), prompt treatment with oral acyclovir is necessary; use intravenous acyclovir for ill, febrile patients 6

Adjunctive Treatments

• Sedating antihistamines may be useful as short-term adjuncts during severe itching episodes, particularly at night 5
• Non-sedating antihistamines have little value in managing hypersensitivity-related rashes 5

Topical Corticosteroid Therapy for Pediatric Eczema

Recommended Topical Corticosteroid Selection

• For children with mild eczema, the American Academy of Pediatrics recommends low-potency corticosteroids (hydrocortisone 1%) 7
• For children with moderate eczema, low to medium potency corticosteroids are recommended 7
• For children with severe eczema, medium to high potency corticosteroids for short periods (3-7 days) are recommended 7

Application Guidelines and Special Considerations

• Treatment should not be applied more than twice daily, as recommended by the British Medical Association 8
• For face, neck, and skin folds, use only low-potency corticosteroids to avoid skin atrophy, as suggested by the British Medical Association and the Journal of Microbiology, Immunology and Infection 8, 9
• For body and limbs, low to medium potency corticosteroids based on severity are recommended by the Journal of Microbiology, Immunology and Infection 7

Maintenance, Prevention, and Alternative Approaches

• Regular use of emollients has a short and long-term steroid-sparing effect, according to the Journal of Microbiology, Immunology and Infection 9, 7
• For moderate to severe eczema, proactive therapy with twice-weekly application of topical corticosteroids to previously affected areas may prevent relapses, as recommended by the Journal of Microbiology, Immunology and Infection 9
• Wet-wrap therapy with topical corticosteroids is an effective short-term second-line treatment for moderate to very severe eczema, as suggested by the Journal of Microbiology, Immunology and Infection 9

Optimal Frequency and Management of Topical Corticosteroids in Adolescent Atopic Dermatitis

Application Frequency

Potency Selection & Step‑Down Strategy

Intermittent Use After Control

Adjunctive Emollient Therapy

Safety Monitoring of Potent Steroids

Addressing Steroid Phobia and Adherence

Duration of Intensive Topical Therapy Before Systemic Options

Management of Treatment Failure and Secondary Infections

Use of Antihistamines for Severe Pruritus

Pharmacological Management of Atopic Dermatitis: Evidence‑Based Recommendations

Topical Therapy and Emollient Use

• Initiate treatment with liberal emollient application combined with the least potent topical corticosteroid that achieves disease control, limiting application to no more than twice daily on affected skin only. 12
• Reserve very potent and potent corticosteroid preparations for short‑term use on thick‑skinned areas (e.g., palms, soles). 12
• Implement “steroid holidays”—temporarily discontinue topical corticosteroids once control is attained—to reduce cumulative exposure and lower the risk of hypothalamic‑pituitary‑adrenal axis suppression. 12
• Prescribe sufficient quantities of emollients and advise patients to apply them liberally and frequently; emollients create a surface lipid film that reduces evaporative water loss. 12
• Replace traditional soaps with soap‑free cleansers or dispersible cream cleansers to preserve the skin’s natural lipids. 12

Adjunctive Topical Agents

• Ichthammol 1 % in zinc ointment is less irritating than coal tar and is particularly useful for lichenified eczema. 12
• Coal tar solution 1 % combined with hydrocortisone ointment provides adequate treatment and does not result in systemic absorption unless used excessively. 12

Management of Pruritus

• Use sedating antihistamines (e.g., hydroxyzine) only at night for severe pruritus episodes; their benefit derives from sedation rather than direct antipruritic action. 12
• Higher doses of sedating antihistamines may be required in pediatric patients. 12
• Non‑sedating antihistamines have little or no therapeutic value in atopic dermatitis and should be avoided. 12

Treatment of Secondary Infections

• When increased crusting, weeping, or pustules are observed, start oral flucloxacillin immediately as the first‑line agent for Staphylococcus aureus infection. 12
• Use phenoxymethylpenicillin if β‑hemolytic streptococci are identified. 12
• Prescribe erythromycin for patients allergic to penicillins or when flucloxacillin resistance is suspected. 12
• Suspect eczema herpeticum in the presence of grouped vesicles, punched‑out erosions, or sudden deterioration with fever, and commence oral acyclovir promptly; this constitutes a medical emergency. 12
• In severely ill or febrile patients with suspected eczema herpeticum, administer acyclovir intravenously. 12

Phototherapy and Systemic Options

• Narrow‑band UVB (312 nm) is effective for moderate‑to‑severe atopic dermatitis when topical regimens are insufficient. 12
• PUVA can be considered but carries long‑term risks of premature skin aging and cutaneous malignancies. 12
• Reserve oral systemic corticosteroids for acute severe flares after all other options have been exhausted; they should not be used for maintenance therapy. 12
• The decision to employ systemic steroids must weigh the potential for pituitary‑adrenal suppression and possible growth interference in children. 12

Safety and Common Pitfalls

• Avoid undertreatment due to steroid phobia; provide clear education on potency differences and risk‑benefit profiles. 12
• Do not apply topical corticosteroids more than twice daily, as this increases adverse effects without enhancing efficacy. 12
• Do not prescribe non‑sedating antihistamines for itch control in atopic dermatitis. 12

Guideline Recommendations for Systemic Therapy in Chronic Atopic Dermatitis

1. Avoidance of Chronic Systemic Corticosteroids

• Systemic corticosteroids (e.g., prednisone) should not be used for chronic management of atopic dermatitis; they are reserved only for acute, severe flares as a short‑term bridge (≤ 1–2 weeks) to steroid‑sparing agents. Guideline recommendation – American Academy of Dermatology. 13
• The American Academy of Dermatology explicitly states that systemic steroids must be avoided whenever possible for both adults and children, limiting use to acute severe exacerbations and brief bridge therapy. Guideline recommendation. 14

2. Acute Use of Prednisone (When Absolutely Necessary)

• Adult dosing: Typical practice is 0.5–1 mg/kg/day (≈ 40–60 mg/day for an average adult). Clinical practice guidance. 15
• Adult duration: Maximum of 1–2 weeks of therapy. Guideline recommendation. 13
• Tapering: Rapid taper over 5–7 days while simultaneously initiating a steroid‑sparing systemic agent. Guideline recommendation. 13
• Bridge agents: Prednisone may be used as a bridge to cyclosporine, dupilumab, methotrexate, or azathioprine. Guideline recommendation. 14
• Pediatric dosing: Weight‑based 0.5–1 mg/kg/day (same range as adults). Clinical practice guidance. 15

3. Preferred Steroid‑Sparing Systemic Agents

3.1 First‑Line Options

• Dupilumab – Recommended as the first‑line biologic for severe, refractory atopic dermatitis; requires no routine laboratory monitoring and has a superior safety profile. Guideline recommendation. 15
• Cyclosporine – First‑line traditional immunosuppressant.
  
  • Adult dose: 2.5–5 mg/kg/day. Guideline recommendation. 13
  • Pediatric dose: 2.5–5 mg/kg/day. Guideline recommendation. 13
  • Monitoring: CBC, comprehensive metabolic panel, magnesium, uric acid, lipids, and blood pressure. Monitoring recommendation. 15

3.2 Second‑Line Options

4. Stepwise Treatment Algorithm for Chronic Atopic Dermatitis

• Optimize topical therapy first – Use high‑potency topical corticosteroids once or twice daily for 1–4 weeks together with liberal emollient use. Guideline recommendation. 15
• Consider phototherapy – Narrow‑band UVB should be trialed before systemic agents when available. Guideline recommendation. 15
• Initiate steroid‑sparing systemic therapy – Prefer dupilumab (if accessible) or cyclosporine as first‑line systemic agents. Guideline recommendation. 13
• Reserve prednisone for crisis – In acute severe flares while awaiting steroid‑sparing therapy effect, limit prednisone to ≤ 1–2 weeks maximum. Guideline recommendation. 14

5. Common Pitfalls to Avoid

• Do not prescribe prednisone for maintenance – Chronic use creates dependence and rebound flares. Guideline warning. 13
• Avoid prolonged tapers – Tapering longer than 2 weeks perpetuates the adverse cycle of chronic steroid exposure. Guideline warning. 14
• Do not delay steroid‑sparing agents – Initiate dupilumab or cyclosporine promptly rather than repeating short courses of prednisone. Guideline warning. 15
• Evidence gaps – Robust data on optimal dosing and duration of short‑term prednisone are lacking; however, consensus strongly advises against chronic use. Guideline statement. 13

Systemic Corticosteroid Use in Severe Atopic Dermatitis – Recommendations and Alternatives

Recommendation to Avoid Systemic Corticosteroids

• The 2024 American Academy of Dermatology (AAD) conditionally recommends against the use of systemic corticosteroids for atopic dermatitis because of low‑certainty evidence and a substantial risk of serious adverse events, including rebound flares and long‑term complications. 16
• In a randomized trial that compared prednisolone with cyclosporine, the study was stopped early due to severe rebound flares in the prednisolone arm, underscoring the danger of steroid‑induced disease flare‑ups. 16
• Rebound flares commonly occur after dose reduction or discontinuation of systemic steroids and often exceed the severity of the initial presentation, making the risk‑benefit balance unfavorable. 16
• Although systemic steroids can produce rapid short‑term improvement, the AAD guideline notes that the overall risk‑benefit ratio does not support their routine use. 17

Situations Where Short‑Term Systemic Steroids May Be Considered

• Systemic corticosteroids may be used only when no other treatment options are immediately available. 16
• They can serve as a bridge to long‑term steroid‑sparing agents such as dupilumab, cyclosporine, methotrexate, or azathioprine, provided the bridge period does not exceed 1–2 weeks and a mandatory taper is applied. 17
• In acute, severe exacerbations while initiating a steroid‑sparing therapy, a brief course of systemic steroids is permissible. 18

Pediatric Considerations

• Children are at increased risk of hypothalamic‑pituitary‑adrenal (HPA) axis suppression and growth impairment when exposed to systemic corticosteroids, warranting heightened caution. 19

Preferred Steroid‑Sparing Systemic Therapies

Biologics (Strong Recommendations)

• Dupilumab is the first‑line biologic for severe atopic dermatitis, offering a superior safety profile and requiring no routine laboratory monitoring. 16
• Tralokinumab also receives a strong recommendation as an effective biologic option. 16

Janus Kinase (JAK) Inhibitors (Strong Recommendations)

• Abrocitinib, baricitinib, and upadacitinib are all strongly recommended for severe disease. Monitoring of complete blood count, liver enzymes, and lipid levels is required during therapy. 16, 19

Traditional Immunosuppressants

• Cyclosporine demonstrated greater efficacy than methotrexate and azathioprine in a network meta‑analysis, supporting its strong recommendation. 16
• Cyclosporine should not be used longer than 12 months because of cumulative renal toxicity. 17
• Methotrexate is most prominently associated with liver damage, reinforcing the need for hepatic monitoring. 17
• Azathioprine’s principal adverse effect is cytopenia, highlighting the importance of blood count surveillance. 17
• Mycophenolate has comparatively limited randomized trial data, making it a less preferred option. 16

Economic and Evidence Context

• Although systemic corticosteroids are less expensive than biologics and JAK inhibitors, the AAD notes that the lower certainty of benefit, higher potential for serious adverse events, and the need for stringent monitoring preclude steroids from being first‑line therapy. 16